Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients - PubMed (original) (raw)
Randomized Controlled Trial
. 2009 Mar 17;33(2):281-5.
doi: 10.1016/j.pnpbp.2008.11.016. Epub 2008 Dec 7.
Affiliations
- PMID: 19110026
- DOI: 10.1016/j.pnpbp.2008.11.016
Randomized Controlled Trial
Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients
Ayse Devrim Başterzi et al. Prog Neuropsychopharmacol Biol Psychiatry. 2009.
Abstract
Background: Several studies demonstrated that depressed patients had low serum BDNF levels which correlated with the severity of their depression, and antidepressant treatment increases levels of serum BDNF in depressed patients. It was speculated that agents acting on both noradrenergic and serotonergic transporters might have a greater influence on BDNF levels. The aim of our study was to determine effects of venlafaxine vs. fluoxetine on serum BDNF levels in depressive patients.
Methods: Forty-three patients diagnosed as major depressive disorder according to DSM-IV are included in the study. Forty-three patients were randomized to take fluoxetine (22 cases) or venlafaxine (21 cases). Serum levels of BDNF were measured by ELISA at baseline and 6 weeks after the start of treatment.
Results: Baseline levels of BDNF were not significantly different between the patient group and the controls. But male patients and the male controls showed statistical differences with respect to baseline BDNF levels. BDNF levels of the patient group did not change with treatment. Yet, the increase of BDNF levels was close to statistically significant in the fluoxetine group, whereas not significant in the venlafaxine group. There were no significant differences in baseline and 6th week BDNF levels between the responders and the non-responders.
Conclusion: Further studies controlling for a wide variety of confounding variables are needed, which may help to reach a clear conclusion about the potential of BDNF as a biomarker for depression or as a predictor of antidepressant efficacy.
Similar articles
- Different serum BDNF levels in depression: results from BDNF studies in FYR Macedonia and Bulgaria.
Ristevska-Dimitrovska G, Shishkov R, Gerazova VP, Vujovik V, Stefanovski B, Novotni A, Marinov P, Filov I. Ristevska-Dimitrovska G, et al. Psychiatr Danub. 2013 Jun;25(2):123-7. Psychiatr Danub. 2013. PMID: 23793275 - Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.
Costa e Silva J. Costa e Silva J. J Clin Psychiatry. 1998 Jul;59(7):352-7. doi: 10.4088/jcp.v59n0703. J Clin Psychiatry. 1998. PMID: 9714263 Clinical Trial. - Once-daily venlafaxine XR compared with fluoxetine in outpatients with depression and anxiety.
Judge R, Wagner BE. Judge R, et al. J Clin Psychiatry. 1999 Nov;60(11):795-6. doi: 10.4088/jcp.v60n1121. J Clin Psychiatry. 1999. PMID: 10584775 No abstract available. - Venlafaxine extended-release: a review of its use in the management of major depression.
Wellington K, Perry CM. Wellington K, et al. CNS Drugs. 2001;15(8):643-69. doi: 10.2165/00023210-200115080-00007. CNS Drugs. 2001. PMID: 11524036 Review. - Clinical evaluation of venlafaxine.
Ballenger JC. Ballenger JC. J Clin Psychopharmacol. 1996 Jun;16(3 Suppl 2):29S-35S; discussion 35S-36S. doi: 10.1097/00004714-199606002-00007. J Clin Psychopharmacol. 1996. PMID: 8784646 Review.
Cited by
- Opposite effects of milnacipran, a serotonin norepinephrine reuptake inhibitor, on the levels of nitric oxide and brain-derived neurotrophic factor in mouse brain cortex.
Ikenouchi-Sugita A, Toyohira Y, Yoshimura R, Ueno S, Tsutsui M, Nakamura J, Yanagihara N. Ikenouchi-Sugita A, et al. Naunyn Schmiedebergs Arch Pharmacol. 2009 Dec;380(6):479-86. doi: 10.1007/s00210-009-0467-z. Epub 2009 Nov 6. Naunyn Schmiedebergs Arch Pharmacol. 2009. PMID: 19894036 - Risks of using SSRI / SNRI antidepressants during pregnancy and lactation.
Dubovicky M, Belovicova K, Csatlosova K, Bogi E. Dubovicky M, et al. Interdiscip Toxicol. 2017 Sep;10(1):30-34. doi: 10.1515/intox-2017-0004. Interdiscip Toxicol. 2017. PMID: 30123033 Free PMC article. Review. - Advances in the Preclinical Study of Some Flavonoids as Potential Antidepressant Agents.
German-Ponciano LJ, Rosas-Sánchez GU, Rivadeneyra-Domínguez E, Rodríguez-Landa JF. German-Ponciano LJ, et al. Scientifica (Cairo). 2018 Feb 1;2018:2963565. doi: 10.1155/2018/2963565. eCollection 2018. Scientifica (Cairo). 2018. PMID: 29623232 Free PMC article. Review. - Meta-analyses of comparative efficacy of antidepressant medications on peripheral BDNF concentration in patients with depression.
Zhou C, Zhong J, Zou B, Fang L, Chen J, Deng X, Zhang L, Zhao X, Qu Z, Lei Y, Lei T. Zhou C, et al. PLoS One. 2017 Feb 27;12(2):e0172270. doi: 10.1371/journal.pone.0172270. eCollection 2017. PLoS One. 2017. PMID: 28241064 Free PMC article. - Serum Brain-Derived Neurotrophic Factors in Taiwanese Patients with Drug-Naïve First-Episode Major Depressive Disorder: Effects of Antidepressants.
Chiou YJ, Huang TL. Chiou YJ, et al. Int J Neuropsychopharmacol. 2017 Mar 1;20(3):213-218. doi: 10.1093/ijnp/pyw096. Int J Neuropsychopharmacol. 2017. PMID: 27811136 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources